Noa Katz Shroitman, MD, BSc
Psychiatry ResidentCards
Contact Info
Psychiatry
60 Temple Street
New Haven, CT 06510
United States
About
Titles
Psychiatry Resident
Biography
As far as I can remember I have always been fascinated by science and especially by the human brain and mind. In fact, mental states are the result of countless converging interactions between genes, brain structures, and biological and environmental cues. Therefore, I believe that a multi-disciplinary approach should be undertaken when coming to investigate this magnificent mechanism. As a biomedical engineer and a psychiatrist, I strive to integrate my knowledge and skills in both the medical and scientific arenas in order to promote research of severe mood disorders and suicide prevention. Currently, I work as post-doctoral associate at the Yale Mood Disorders Research Program, under Professor Hilary Blumberg. My research focuses on severe mood disorders, such as bipolar disorder and major depression, studying their effect on brain structure and function using state-of-the-art technologies such as advanced magnetic resonance imaging, functional near-infrared spectroscopy (FNIRS) and genetic and stem cell technologies.
Education & Training
- Psychiatry Residency
- Tel Aviv Medical Center (Ichilov), Tel Aviv, Israel (2022)
- Psychosocial Evaluator of Medical School Candidates
- Israel National Institute for Testing and Evaluation (2022)
- Non Degree Program
- School of Medicine, Tel Aviv University, Continuing Medical Education in Psychopathology and Psychotherapy (2022)
- Non Degree Program
- School of Medicine, Tel Aviv University, Women Mental Health- "Fertility and Beyond" (Biological, mental and social aspects of women health) (2021)
- MD
- School of Medicine, Tel Aviv University (2018)
- Medical Clinical Internship (Cum Laude)
- Shamir (Assaf Harofeh) Medical Center, Be'er Ya'akov, Israel (2018)
- Clinical Elective
- Weill Cornell Medicine, NY (2016)
- BSc
- Technion Israel Institute of Technology, Haifa, Israel, Biomedical Engineering (2009)
Research
Overview
Current research work:
I am a post-doctoral associate at the Yale Mood Disorders Research Program, under Professor Hilary Blumberg. My research work includes conducting multi-disciplinary clinical research with focus on bipolar disorder in adults and adolescents, targeting underlying brain circuitry in major mood disorders. I am involved in various research projects including neuroimaging study that correlated polygenic risk score (PRS) for suicidality in bipolar disorder with differentiation in brain structures, stem cell study that focus on mitochondrial aberration in bipolar disorder, and biological rhythms study. As part of research work, conducting clinical interviews and cognitive assessments of research subjects, neuroimaging preprocessing, clinical writing and statistical analysis.
Previous research work:
Project title: Meta-analysis of ATP synthase encoding genes expression in brain samples of patients with schizophrenia
Mentors: Prof. Dorit Ben-Shachar (Technion, Israel), Prof. David Gurwitz (Tel Aviv University, Israel) and Dr. Libi Herzberg (Weizmann Institute of Science, Israel)
Conducted systematic meta-analysis to explore the differential expression of the genes encoding the mitochondrial ATP synthase enzyme in schizophrenia postmortem brain samples (from rostral prefrontal cortex (Brodmann Area 10 (BA10)), superior temporal gyrus (STG) BA22 and the cerebellum). Most ATP synthase encoding genes tend to be down-regulated in schizophrenia; 2 of the 16 (12.5%), ATP5A1 and ATP5H genes, were significantly down-regulated. One gene showed a non-significant trendfor up-regulation, ATP5G2. The tendency for down-regulation was shown for both males and females.
accepted for publication in the Journal of Psychiatric Research
Project title: Reward system dysfunction in depressive withdrawal in Parkinson’s disease compared with major depressive disorder
Mentor: Dr. Iftah Biran (Neurology, Tel Aviv Sourasky Medical Center, Israel)
We recently showed (Biran, 2019) that depressed patients manifest an inward spatial bias, leading them to bisect lines presented on a radial axis closer to them as compared with heathy controls. This bias can be explained through a narcissistic model of depression according to which depressed patients withdraw into their inner world. We suggested this effect may be mediated by down regulation of the dopaminergic "Seeking System", also referred to as the “Reward System” originating in the frontal tegmentum that regulates the responsiveness to outside world stimuli. This system is damaged early in Parkinson's disease. In this questionnaire-based controlled clinical study, we further examined spatial bias and its associations with measures of the seeking/reward system and of narcissism, and compared these measures across three groups: (1) patients with Parkinson’s disease, (2) patients with major depressive disorder without Parkinson’s disease, and (3) healthy controls. A manuscript based on these results is in preparation
Project title: Janssen-Cilag clinical trial (ESCAPE-TRD): A long-term comparison of Esketamine nasal spray versus Quetiapine extended release
Mentor: Dr. Oren Tene (Psychiatry, Tel Aviv Sourasky Medical Center, Israel)
This Janssen-Cilag Pharmaceutical-sponsored 36-week study compares esketamine nasal spray to quetiapine extended-release (XR), each in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission for participants who have treatment-resistant major depressive disorder (TRD) with a current moderate to severe depressive episode. Primary Outcome Measures: percentage of participants with remission as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) (total score of <= 10)
Project title: Acute pancreatitis caused by Clozapine treatment
Mentor: Dr. Oren Tene (Psychiatry, Tel Aviv Sourasky Medical Center, Israel)
Pancreatitis has been established as a rare but potentially fatal side effect of clozapine treatment, but reports about incidence remain relatively low, with only 9 reports by 2020. Thus, this report of acute pancreatitis following the initiation of clozapine treatment is of extreme importance, as clinicians must remain alert to the possibility and circumstances of its occurrence. (Manuscript under review)
Project title: False-positive fentanyl screening kit results during treatment with long term
injectable risperidone (Risperdal-Consta)
Mentor: Prof. Shaul Shreiber (Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center, Israel)
Fentanyl, a highly potent synthetic opioid, is a major cause of overdose deaths in the United
States and worldwide. Urine drug immunoassay tests that include fentanyl in their drug panel
are the common screening tool. However, false positive results may compromise test accuracy
and cause grave clinical outcomes. In this preliminary report we describe 3 cases of patients
with schizophrenia treated with long-term injectable risperidone (Risperdal Consta) who has a false positive screen for fentanyl by a rapid commercial screening kit. This finding warrants clinical attention to the possibility of inaccurate results regarding fentanyl misuse in multiple clinical settings.
08/2014 – 06/2016 Project title: Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity
Mentor: Prof. Baruch Brenner, (Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel)
This is a retrospective cohort study, identifying the differences in demographics, clinical presentation, histological characteristics, therapeutic approach, toxicity and clinical outcomes between colorectal cancer patients aged 80 years or older to patients younger than 80 years.
06/2008 – 09/2009 Project title: Polymer-conjugated albumin and fibrinogen composite hydrogels as cell scaffolds designed for affinity-based drug delivery
Mentor: Prof. Dror Seliktar (Tissue Engineering and Biomaterials Lab, Technion Institute of Technology, Haifa, Israel)
Serum albumin was conjugated to poly-ethylene glycol (PEG) and cross-linked to form mono-PEGylated albumin hydrogels. These hydrogels were used as a basis for drug carrying tissue engineering scaffold materials
06/2008 – 09/2009 Project title: Development of a drug-eluting biodegradable ureteral stent
Mentor: Prof. Daniel Ichia (ALLIUM Medical Urological Solutions, Caesarea Industrial Park South, Israel)
BME graduation project performed in the biomedical Industry, in which I have joined the company R&D team to develop a drug-eluting biodegradable ureteral stent. The project was selected for BME faculty outstanding graduation projects
Medical Subject Headings (MeSH)
Academic Achievements and Community Involvement
activity Israel Medical Association
Professional OrganizationsPhysicianDetails2018 - Presentactivity Technion (Israel Institute of Technology) Alumni
Professional OrganizationsMemberDetails2009 - Presentactivity Israel Society of Biological Psychiatry (ISBP)
Professional OrganizationsMemberDetails2018 - 2022activity LEMA’ANAM (“for them” in Hebrew) physicians for holocaust survivors
Public ServiceVolunteerDetailsProviding accessible medical care to holocaust survivors2020 - 2022
Get In Touch
Contacts
Psychiatry
60 Temple Street
New Haven, CT 06510
United States